Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer

Jönsson, M LU ; Borg, A LU ; Nilbert, M LU and Andersson, T LU (2000) In European Journal of Cancer 36(2). p.8-242
Abstract

We studied the relevance of adenomatous polyposis coli (APC)/beta-catenin signalling in the development of breast cancer by analysing the expression of beta-catenin in 54 primary breast tumours (34 ductal and 20 lobular). We showed that 13% of the tumours exhibited upregulated levels of beta-catenin in the cytosol suggesting that defects in APC/beta-catenin signalling components had lowered the rate of beta-catenin degradation. No mutations were observed in the amino-terminal region of beta-catenin, which comprises conserved serine residues important for phosphorylation-dependent degradation of the protein, but the APC protein was altered in 6% of the tumours. Tyrosine phosphorylation of beta-catenin was detected in only one tumour and... (More)

We studied the relevance of adenomatous polyposis coli (APC)/beta-catenin signalling in the development of breast cancer by analysing the expression of beta-catenin in 54 primary breast tumours (34 ductal and 20 lobular). We showed that 13% of the tumours exhibited upregulated levels of beta-catenin in the cytosol suggesting that defects in APC/beta-catenin signalling components had lowered the rate of beta-catenin degradation. No mutations were observed in the amino-terminal region of beta-catenin, which comprises conserved serine residues important for phosphorylation-dependent degradation of the protein, but the APC protein was altered in 6% of the tumours. Tyrosine phosphorylation of beta-catenin was detected in only one tumour and could, therefore, not have been responsible for the observed increased levels of this protein. Although 9% of the tumours displayed upregulation of c-MYC protein, there was no correlation with beta-catenin overexpression, suggesting that increased beta-catenin expression is not the major cause of c-myc gene activation in breast cancer. It is imperative that elements that selectively drive the oncogenic activity of beta-catenin in breast cancer be identified.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adenomatous Polyposis Coli Protein, Adult, Blotting, Western, Breast Neoplasms/genetics, Carcinoma, Ductal, Breast/genetics, Carcinoma, Lobular/genetics, Cell Communication, Cytoskeletal Proteins/metabolism, Female, Humans, Mutation/genetics, Neoplasm Proteins/metabolism, Sweden, Trans-Activators, beta Catenin
in
European Journal of Cancer
volume
36
issue
2
pages
7 pages
publisher
Elsevier
external identifiers
  • pmid:10741284
  • scopus:0033976526
ISSN
0959-8049
language
English
LU publication?
yes
id
556c7d5a-d989-427d-9bf6-ce1468df9dcb
date added to LUP
2019-06-20 11:38:40
date last changed
2024-05-15 13:48:38
@article{556c7d5a-d989-427d-9bf6-ce1468df9dcb,
  abstract     = {{<p>We studied the relevance of adenomatous polyposis coli (APC)/beta-catenin signalling in the development of breast cancer by analysing the expression of beta-catenin in 54 primary breast tumours (34 ductal and 20 lobular). We showed that 13% of the tumours exhibited upregulated levels of beta-catenin in the cytosol suggesting that defects in APC/beta-catenin signalling components had lowered the rate of beta-catenin degradation. No mutations were observed in the amino-terminal region of beta-catenin, which comprises conserved serine residues important for phosphorylation-dependent degradation of the protein, but the APC protein was altered in 6% of the tumours. Tyrosine phosphorylation of beta-catenin was detected in only one tumour and could, therefore, not have been responsible for the observed increased levels of this protein. Although 9% of the tumours displayed upregulation of c-MYC protein, there was no correlation with beta-catenin overexpression, suggesting that increased beta-catenin expression is not the major cause of c-myc gene activation in breast cancer. It is imperative that elements that selectively drive the oncogenic activity of beta-catenin in breast cancer be identified.</p>}},
  author       = {{Jönsson, M and Borg, A and Nilbert, M and Andersson, T}},
  issn         = {{0959-8049}},
  keywords     = {{Adenomatous Polyposis Coli Protein; Adult; Blotting, Western; Breast Neoplasms/genetics; Carcinoma, Ductal, Breast/genetics; Carcinoma, Lobular/genetics; Cell Communication; Cytoskeletal Proteins/metabolism; Female; Humans; Mutation/genetics; Neoplasm Proteins/metabolism; Sweden; Trans-Activators; beta Catenin}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{8--242}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer}},
  volume       = {{36}},
  year         = {{2000}},
}